Thus, oncoVV-AVL reprograms HCC metabolism by inducing ACSS2/TFEB-driven autophagy and lipid metabolic switching, which synergize with its direct oncolytic activity (Figure 5C). The gene discussed is ACSS2; the disease is hepatocellular carcinoma.